Cited by 385Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

Spencer, Thomas, Biederman, Joseph, Wilens, Timothy, Doyle, Robert, Surman, Craig, Prince, Jefferson, Mick, Eric, Aleardi, Megan, Herzig, Kathleen, Faraone, Stephen·2005·Biological Psychiatry

DOI 10.1016/j.biopsych.2004.11.043

Open this paper in CoChat — free account

Abstract

Background The few controlled studies of methylphenidate (MPH) in adults with attention deficit/hyperactivity disorder (ADHD) have reported equivocal results. A previous, pilot study by our group suggested that these results were due to inadequate dosing. Method We conducted a randomized, 6-week, placebo-controlled, parallel study of MPH in 146 adult patients with DSM-IV ADHD using standardized instruments for diagnosis, separate assessments of ADHD, depressive and anxiety symptoms, and a robust average oral daily dose of 1.1 mg/kg/day. Results We found a marked therapeutic response for the MPH treatment of ADHD symptoms that exceeded the placebo response (76% vs. 19%). Treatment was safe and well tolerated. Response to MPH was independent of socioeconomic status, gender, and lifetime history of psychiatric comorbidity. Conclusions These results confirm that robust doses of MPH are effective in the treatment of adult ADHD.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2004.11.043

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
Four Factor Index of Social Status
Paschou, R. (1975) · Cited by 6,989
Four Factor Index of Social Status [1975]
Hollingshead, A. B. (1975) · Cited by 5,151
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
Barkley, R. A., & Poillion, M. J. (1994) · Behavioral Disorders · doi:10.1177/019874299401900205 · Cited by 4,635

Show all 60 references

Research works printed but not linked: 3

Faraone, 2003, The worldwide prevalence of ADHD, World Psychiatry, 2, 104
1985, CGI (Clinical Global Impression Scale)—NIMH, Psychopharmacol Bull, 21, 839
Spencer, 2004, Diagnostic approaches to adult ADHD, Prim Psychiatry, 11, 49

Sorted by citations

Items 201–300 of 385

Differences in Psychiatric Problems and Criminality Between Individuals Treated With Central Stimulants Before and After Adulthood
Rasmussen, K., Palmstierna, T., & Levander, S. (2019) · Journal of Attention Disorders · doi:10.1177/1087054715571740 · Cited by 10
Brain Arousal Regulation in Carriers of Bipolar Disorder Risk Alleles
Jawinski, P., Sander, C., Mauche, N., Spada, J., Huang, J., Schmidt, A., Häntzsch, M., Burkhardt, R., Scholz, M. R., Hegerl, U., et al. (2015) · Neuropsychobiology · doi:10.1159/000437438 · Cited by 13
Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort
Lemelin, M., Boukhris, T., Zhao, J.-P., Sheehy, O., & Bérard, A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.781 · Cited by 10
Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development
Chirokikh, A., Uddin, S. M. Z., Areikat, N., Jones, R., Duque, E., Connor, C., Hadjiargyrou, M., Thanos, P. K., & Komatsu, D. E. (2022) · Bone · doi:10.1016/j.bone.2022.116637 · Cited by 13
Risques cardiovasculaires et conduite à tenir dans le traitement du trouble déficit de l’attention/hyperactivité avec le méthylphénidate
Bange, F., Heuzey, M.-F. L., Acquaviva, É., Delorme, R., & Mouren, M. (2013) · Archives de Pédiatrie · doi:10.1016/j.arcped.2013.11.001 · Cited by 13
Current issues and trends in the diagnosis and treatment of adults with ADHD
Cumyn, L., Kolar, D., Keller, A., & Hechtman, L. T. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1375 · Cited by 13
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
Zimovetz, E. A., Joseph, A., Ayyagari, R., & Mauskopf, J. A. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-016-0864-4 · Cited by 13
“98 mg per day), and the average dose for the post-titration period (82 mg per day) was taken from a safety trial of MPH-IR in adults with ADHD identified by the systematic review [35].”
Methylphenidatbehandlung bei Erwachsenen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
Sobanski, E., Alm, B., & Krumm, B. (2006) · Der Nervenarzt · doi:10.1007/s00115-006-2068-0 · Cited by 13
Understanding the causal relationships of attention-deficit/hyperactivity disorder with mental disorders and suicide attempt: a network Mendelian randomisation study
Meisinger, C., & Freuer, D. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2022-300642 · Cited by 12
START – physical exercise and person-centred cognitive skills training as treatment for adult ADHD: protocol for a randomized controlled trial
Lindvall, M. A., Lidström-Holmqvist, K., Svedell, L. A., Philipson, A., Cao, Y., & Msghina, M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05181-1 · Cited by 12
“The response rate to pharmacological treatment is high; however, up to 30% of patients fail to respond to CS medication [13].”
Background
Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD
Spencer, T. J., Bhide, P. G., Zhu, J., Faraone, S. V., Fitzgerald, M., Yule, A. M., Uchida, M., Spencer, A. E., Hall, A. M., Koster, A. J., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11012 · Cited by 12
Self-citation
A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder
Joshi, G., DiSalvo, M., Wozniak, J. R., Ceranoglu, T. A., Yule, A. M., Surman, C. B. H., Fried, R. S., Galdo, M., Hoskova, B., Belser, A. H., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679392 · Cited by 12
“Analogous to study design in adult anti-ADHD trials (Spencer et al. 2005; Biederman et al. 2006; Adler et al. 2009), our a priori definition of response was defined as end-point reduction in the severity of ADHD symptoms based on 30% reduction in the AISRS total score and ADHD-CGI-I score of 2.”
MethodSelf-citation
Pharmacological treatment of attention-deficit/hyperactivity disorder in adults
Slatkoff, J., & Greenfield, B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.649 · Cited by 15
“The long-term impact of adverse events with MPH in adults is not known at this point as the longest trial to date is 18 weeks [15], with most trials lasting 3 – 7 weeks [6,7,9,11].”
BackgroundResultInfluential
Pharmacotherapy of ADHD in adults
Prince, J. B., Morrison, N. R., & Wilens, T. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.023 · Cited by 11
Self-citation
Risk of Methylphenidate‐Induced Prehypertension in Normotensive Adult Smokers With Attention Deficit Hyperactivity Disorder
Westover, A. N., Nakonezny, P. A., Winhusen, T. M., Adinoff, B. H., & Vongpatanasin, W. (2012) · Journal of Clinical Hypertension · doi:10.1111/jch.12039 · Cited by 11
Special Considerations in Diagnosing and Treating Attention-Deficit/Hyperactivity Disorder
Wigal, S. B., & Wigal, T. L. (2007) · CNS Spectrums · doi:10.1017/s1092852900026092 · Cited by 11
Attention-deficit/hyperactivity disorder (ADHD) in adults: a multilayered approach to a serious disorder of inattention to the future
Palmini, A. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0044-1791513 · Cited by 25
The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria
Spencer, T. J., Bhide, P. G., Zhu, J., Faraone, S. V., Fitzgerald, M., Yule, A. M., Uchida, M., Spencer, A. E., Hall, A. M., Koster, A. J., et al. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11609 · Cited by 10
Self-citation
The Relationship Between Response-Inhibitory Event-Related Potentials and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adult Patients with Major Depressive Disorder
Kim, E. J., Kwon, Y., Lee, H.-Y., Yoon, H. J., Kim, J. S., & Shim, S.-H. (2020) · Psychiatry Investigation · doi:10.30773/pi.2020.0074 · Cited by 10
High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes.
Mech, A. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816745de · Cited by 9
The effect of methylphenidate on pain perception thresholds in children with attention deficit hyperactivity disorder
Bozkurt, A., & Balta, S. (2023) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-023-00667-y · Cited by 9
“Stimulants effectively reduce attention deficits and sensation-seeking behavior in individuals with ADHD [54, 55].”
Background
Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder
Conzelmann, A., Woidich, E., Mucha, R. F., Weyers, P., Müller, M., Lesch, K., Jacob, C., & Pauli, P. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1512-y · Cited by 10
“The psychopharmacological function of MPH in ADHD is mainly explained by an increase of dopamine and noradrenalin availability (Pliszka 2005; Wilens 2008) which reduces core symptoms of hyperactivity, impulsivity and inattentiveness (Spencer et al. 2005).”
Background
Attention-Deficit Hyperactivity Disorder in Adults and Children: ADHD diagnostic and symptom assessment scales for adults
Adler, L., Shaw, D. M., & Alperin, S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.019 · Cited by 7
“” The AISRS has been shown sensitive to drug effects in clinical trials of adults [50, 51]”
Background
Attention-Deficit/Hyperactivity Disorder Symptom Profiles in Medication-Treated Adults Entering a Psychosocial Treatment Program.
Knouse, L. E., Sprich, S. E., Cooper‐Vince, C. E., & Safren, S. A. (2009) · PubMed · Cited by 9
Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder
Anbarasan, D., Safyer, G., & Adler, L. A. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.008 · Cited by 9
Attention-Deficit Hyperactivity Disorder in Adults: An Overview
Wender, P. H., & Tomb, D. A. (2009) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000258447 · Cited by 9
Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder
Kowalik, S. C., Minami, H., & Silva, R. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.18.2547 · Cited by 9
“2 Changes in weight Examining the results of the 7-week study [60], it was noted that the weight loss associated with D-MPH XR averaged about half a kilogram and differed significantly from placebo.”
Background
The Weighed Core Symptom Scale and Prediction of ADHD in Adults – Objective Measures of Remission and Response to Treatment with Methylphenidate
Edebol, H., Helldin, L., & Norlander, T. (2013) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901309010171 · Cited by 11
“Studies of goal-directed management with first-line treatment for ADHD demonstrate satisfactory results and patients may respond to the point that they become essentially asymptomatic and clinical criteria are no longer fulfilled [10-12].”
Background
Treating Adult ADHD with Stimulants
Stein, M. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900026845 · Cited by 9
Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care.
Adler, M., Barkley, R., Newcorn, M. J. H., Spencer, M. T., Weiss, M. D., Dr, E. L., & Newcorn (2007) · The Primary Care Companion to the Journal Clinical Psychiatry · doi:10.4088/pcc.v09n0207 · Cited by 12
Le trouble déficit de l’attention/hyperactivité à l’âge adulte : concept, tableau clinique, stratégies diagnostiques et thérapeutiques
Blondeau, C., Rénéric, J.-P., Martin‐Guehl, C., & Bouvard, M. P. (2009) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2009.01.016 · Cited by 8
Validade de constructo e confiabilidade da versão em língua portuguesa do Questionário de Qualidade de Vida em Adultos que apresentam TDAH (AAQoL)
Mattos, P., Segenreich, D., Dias, G. M., Nazar, B. P., Saboya, E., & Broad, M. E. (2011) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832011000300002 · Cited by 8
The Safety and Efficacy of Methylphenidate and Dexmethylphenidate in Adults with Attention Deficit/Hyperactivity Disorder
Sopko, M. A., Caberwal, H., & Chavez, B. (2010) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4178 · Cited by 8
“…N (MPH/PLA) Dosing titration Mean daily MPH/mean daily PLA (max MPH dose/d) Efficacy results (MPH/PLA) Safety results (MPH/PLA) Additional notes Spencer et al 2005 (MPH) DB, rando- mized to MPH or PLA at a ratio of 2.5:1, parallel, PLAcontrolled, 6 wks 19–60 yrs, met DSM-iv criteria of ADHD…”
Influential
Lack of Association Between a 3’UTR VNTR Polymorphism of Dopamine Transporter Gene (SLC6A3) and ADHD in a Brazilian Sample of Adult Patients
da Silva, M. R. A., Cordeiro, Q., Louzã, M., & Vallada, H. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710365989 · Cited by 8
“Psychostimulants, such as methylphenidate (MPH) and dexamphetamine, are widely accepted as the treatment of choice in the pharmacotherapy of ADHD patients with high response rates up to 70% of adults (Spencer et al., 1995, 2005).”
Background
OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder
Ramos‐Quiroga, J. A., Corominas, M., Cervelló, X. C., Bosch, R., & Casas, M. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.65 · Cited by 7
The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (III) - Pharmacological Treatment -
Kim, H., Kim, E. J., Kim, J.-H., Park, J., Bahn, G. H., Lee, Y. J., Jhung, K., & Shin, D. (2017) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.2017.28.2.70 · Cited by 8
Methylphenidat
Paslakis, G., Kiefer, F., Diehl, A., Alm, B., & Sobanski, E. (2010) · Der Nervenarzt · doi:10.1007/s00115-009-2916-9 · Cited by 8
Varieties of Psychotherapy for Attention‐Deficit Hyperactivity Disorder
Dobrean, A., Păsărelu, C. R., & Döpfner, M. (2017) · Wiley eBooks · doi:10.1002/9781119462996.ch16 · Cited by 8
Tratamiento de la manía aguda con metilfenidato: propuesta terapéutica basada en un nuevo modelo fisiopatológico
López-García, P., & Hegerl, U. (2012) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2012.09.001 · Cited by 7
First‐Dose Methylphenidate‐Induced Changes in the Anti‐Saccade Task Performance and Outcome in Adults with Attention‐Deficit/Hyperactivity Disorder
Duval, F., Erb, A., Mokrani, M., Weiss, T., & Carcangiu, R. (2021) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20210010 · Cited by 7
“In accordance with the existing literature (11), about two‐thirds of our ADHDs experienced clinical remission after 6 months of MPH treatment.”
BackgroundResult
Borderline personality disorder is an innate empathy anomaly: a scoping and narrative review
Hayward, D., MacIntyre, D. J., & Steele, J. D. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2024.2420662 · Cited by 9
“Psychological treatments are the cornerstone of treatment’ (NICE., 2009) while, in contrast, in ADHD, there is ‘good evidence for effects of medication on reducing ADHD symptom’s (Spencer et al., 2005) but ‘only limited evidence for effects of psychological treatments’ (NICE, 2019)].”
Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
McDonagh, M. S., & Peterson, K. (2011) · Cited by 7
Neural and Cognitive Predictors of Stimulant Treatment Efficacy in Medication-Naïve ADHD Adults: A Pilot Diffusion Tensor Imaging Study
Hung, Y., Green, A., Kelberman, C., Gaillard, S. L., Capella, J., Rudberg, N., Gabrieli, J. D. E., Biederman, J., & Uchida, M. (2024) · Journal of Attention Disorders · doi:10.1177/10870547231222261 · Cited by 7
“Attention Deficit Hyperactivity Disorder (ADHD), which affects an estimated 11% of children and adolescents and 4.4% of adults (Spencer et al., 2005; Weisler et al., 2006), is the most common neurodevelopmental disorder that results in significantly reduced quality of life.”
BackgroundInfluentialSelf-citation
Sleep and Quality of Life in ADHD
Bekker, E. M., Kooij, J. J. S., & Buitelaar, J. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-343-5_28 · Cited by 7
Attention-Deficit Hyperactivity Disorder Across the Lifespan
Pliszka, S. R. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150022 · Cited by 10
ADHD symptoms in adults with delayed sleep phase disorder
Snitselaar, M. A., Smits, M. G., & Spijker, J. (2018) · Sleep and Biological Rhythms · doi:10.1007/s41105-018-0188-0 · Cited by 7
Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Verbeeck, W., Bekkering, G. E., & Noortgate, W. V. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009504 · Cited by 7
Diagnosing ADHD in adults
Adler, L. A., & Shaw, D. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511780752.009 · Cited by 7
Kardiovaskulær risikovurdering ved bruk av AD/HD-medikamenter hos barn
Berg, A., Bråtane, E., Odland, H. H., Brudvik, C. E., Rosland, B., & Hirth, A. (2014) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0565 · Cited by 8
Atomoxetine in clinical practice
Weiss, M. D., Virani, A. S., Wasdell, M. B., Faulkner-Gibson, L., Rea, K., Fréeman, R. D., Weiss, G., & Jokhani, V. (2006) · Future Neurology · doi:10.2217/14796708.1.3.249 · Cited by 7
“Contrary to common belief, even with stimulant use, patients continue to show some further decline in symptoms after the initial dramatic drop seen in the first month [9–11].”
Result
Pharmakotherapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter
Kordon, A., & Fallahpour, M. H. (2006) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.54.2.99 · Cited by 6
Methylphenidate treatment of adult ADHD patients improves the degree of ADHD severity under routine conditions
Retz, W., Rösler, M., Fischer, R., Ose, C., & Ammer, R. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02226-7 · Cited by 8
Correlates and Treatment Outcome of Risky Sexual Behaviour in Young Males with ADHD and Comorbid Alcohol Use Disorder: A Prospective Study
Kumar, S., Devendran, Y., Madhumitha, N. S., & Thejas, J. A. (2019) · Journal of Psychosexual Health · doi:10.1177/2631831818824437 · Cited by 5
Driving and Road Rage Associated with Attention Deficit Hyperactivity Disorder (ADHD): a Systematic Review
Deshmukh, P., & Patel, D. D. (2019) · Current Developmental Disorders Reports · doi:10.1007/s40474-019-00183-9 · Cited by 8
Quality of Life with Flotation Therapy for a Person Diagnosed with Attention Deficit Disorder, Atypical Autism, PTSD, Anxiety and Depression
Kjellgren, A., Edebol, H., Nordén, T., & Norlander, T. (2013) · Open Journal of Medical Psychology · doi:10.4236/ojmp.2013.23020 · Cited by 6
“toms may be effectively treated with medications [10] but secondary symptoms of both ADHD, autistic and comorbid disorders also require a more general approach including sometimes non-traditional therapies for symptom-relief, healthy life-changes, quality of life and everyday functioning [8,9].”
Background
The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (IV) - Non-Pharmacologic Treatment -
Shin, Y., Kim, E., Kim, Y., Bhang, S., Lee, E., Lee, C.-S., Chang, H. Y., Hong, M., & Shin, D. (2017) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.2017.28.2.84 · Cited by 6
Oral Controlled Release‐Based Products for Life Cycle Management
Davar, N., & Ghosh, S. (2010) · doi:10.1002/9780470640487.ch18 · Cited by 6
Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions
Tcheremissine, O. V., & Salazar, J. O. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1299 · Cited by 17
Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial
Gamal, F., Agami, O. E., & Salamah, A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666211124093345 · Cited by 5
The Status of Boyhood Studies
Chu, J. Y., Drummond, M., Redman, P., Fine, G. A., Morrell, R. G., Keddie, A., Korobov, N., Janssen, D. F., Pallotta‐Chiarolli, M., Kehily, M. J., et al. (2009) · Boyhood Studies · doi:10.3149/thy.0301.111 · Cited by 5
Adult Attention-Deficit Hyperactivity Disorder
Knouse, L. E., & Safren, S. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-387-5_9 · Cited by 5
“Importantly, the clinician-rated version of the ASRS, the AISRS, has been sensitive to treatment-related change in three recent studies [13][14][15].”
Assessment and Treatment of ADHD in People Over 60
Kooij, J. J. S., Bijlenga, D., & Michielsen, M. (2019) · The ADHD Report · doi:10.1521/adhd.2019.27.4.1 · Cited by 6
Exploration of electroencephalogram response to MPH treatment in ADHD patients
Takahara, Y., Ota, T., Nakanishi, Y., Ueda, S., Jurica, P., Struzik, Z. R., Nishitomi, K., Iida, J., Kishimoto, T., Cichocki, A. S., et al. (2023) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2023.111631 · Cited by 5
Stimulant Treatment and Potential Adverse Outcomes in Pediatric Populations With Bipolar Disorder: A Systematic Review of the Literature
O’Connor, H., Vater, C. H., DiSalvo, M., Faraone, S. V., & Wozniak, J. R. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231218045 · Cited by 5
“In general, stimulants have been shown to be exceed-ingly effective, safe, and well-tolerated for treating children and adults with ADHD (Biederman et al., 2006; Riera et al., 2017; Spencer et al., 2005); however, serious adverse events have been reported.”
BackgroundSelf-citation
Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder.
Olfson, M., Marcus, S., Zhang, H.-B. F., & Wan, G. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816740be · Cited by 4
Pharmacology of Adult ADHD with Stimulants
Spencer, T. (2007) · CNS Spectrums · doi:10.1017/s1092852900026018 · Cited by 6
Self-citation
Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks
Manjanatha, M. G., Shelton, S. D., Dobrovolsky, V. N., Shaddock, J. G., McGarrity, L. G., Twaddle, N. W., Moore, M. M., Mattison, D. R., Slikker, W., & Morris, S. M. (2009) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2009.09.004 · Cited by 5
Managing ADHD in Adults with Common Comorbidities
Sobanski, E., Paslakis, G., Schredl, M., Daffner, S., & Alm, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-248-3_8 · Cited by 6
Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD – A phase 2A clinical trial
Radin, D. P., Cerne, R., Smith, J. L., Witkin, J. M., & LIPPA, A. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178047 · Cited by 5
Sex differences in the response to treatment of attention deficit hyperactivity disorder
Müller, E. D., & Fender, A. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04716-5 · Cited by 4
“Overall, methylphenidate is generally well-tolerated, and older data suggest that clinical responses are largely independent of socioeconomic status, lifetime history of psychiatric comorbidity, and sex, at least over short-term use (Pelham et al. 1989; Spencer et al. 2005; Mikami et al. 2009).”
Correlating family nurse practitioners' perspectives of adult ADD/ADHD with employed pharmacotherapy: A pilot study
Martinson, J., & Tang, H.-Y. J. (2010) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00527.x · Cited by 4
“These stimulants have been shown to be effective in controlled studies (Biederman et al., 2006; Spencer et al., 2005).”
Comparison of Two brands of Methylphenidate (Stimdate(®) vs. Ritalin(®)) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.
Khodadust, N., Jalali, A., Ahmadzad-Asl, M., Khademolreza, N., & Shirazi, E. (2012) · Europe PMC (PubMed Central) · Cited by 4
ADHD psychopharmacology across the lifespan
Vitiello, B. (2009) · Current Attention Disorders Reports · doi:10.1007/s12618-009-0010-7 · Cited by 4
Trouble bipolaire et trouble déficit d’attention avec hyperactivité
Besnier, N. (2009) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2009.09.004 · Cited by 4
“Les psychostimulants tels que le méthylphénidate restent le traitement de référence du TDAH, tandis que certains antidépresseurs comme le bupropion ou l’atomoxetine semblent particulièrement prometteurs [6,16,22].”
Background
Disparities in activity levels and learning ability between Djungarian hamster (Phodopus sungorus) and Roborovskii hamster (Phodopus roborovskii)
Ikeda, H., Nagasawa, M., Yamaguchi, T., Minaminaka, K., Goda, R., Chowdhury, V. S., Yasuo, S., & Furuse, M. (2016) · Animal Science Journal · doi:10.1111/asj.12659 · Cited by 4
Effectiveness of Pharmacological Treatments for Adult ADHD on Psychiatric Comorbidity: A Systematic Review
Tripodi, B., Carbone, M. G., Matarese, I., Rizzato, R., Rocca, F. D., Dominicis, F. D., & Callegari, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248848 · Cited by 4
“Consistent with the studies mentioned above, two 6-week randomized controlled trials from the same research group, involving a large sample of adults with ADHD and comorbid affective and/or anxiety disorders, did not find a significant effect of MPH on mood or anxiety compared with placebo [29,32].”
Psychopharmacological Treatment of Attention-Deficit Hyperactivity Disorder in Adults
Trott, G. (2009) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000258456 · Cited by 2
Bad medicine: adult attention-deficit/hyperactivity disorder
Spence, D. (2011) · BMJ · doi:10.1136/bmj.d7244 · Cited by 3
Contrasting expectancy effects with objective measures in adults with untreated ADHD during QbTest
Löhman, M., Domingo, B., Östlund, M., & Jansson, L. (2023) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12906 · Cited by 3
Factors related to methylphenidate response in children with attention deficit/ hyperactivity disorder: a retrospective study
Say, G. N., Karabekiroğlu, K., & Yuce, M. (2015) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2015280403 · Cited by 3
The “VIP-ADHD trial”: Does brain arousal have prognostic value for predicting response to psychostimulants in adult ADHD patients?
Strauß, M., Petroff, D., Huang, J., Ulke, C., Paucke, M., Bogatsch, H., Böhme, P., Hoffmann, K., Reif, A., Kittel‐Schneider, S., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.12.003 · Cited by 3
Self-evaluated burden in adults with attention-deficit hyperactivity disorder (ADHD): a pilot study
Mattos, P., Dias, G. M., Segenreich, D., & Malloy‐Diniz, L. F. (2010) · Jornal Brasileiro de Psiquiatria · doi:10.1590/s0047-20852010000400009 · Cited by 3
The Art of Prescribing Pharmacological Management of Adult ADHD: Implications for Psychiatric Care
Antai-Otong, D. (2008) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2008.00174.x · Cited by 3
Methylphenidat - Therapieoption bei ADHS und Suchterkrankung im Erwachsenenalter?
Paslakis, G., Kiefer, F., Diehl, A., Alm, B., & Sobanski, E. (2010) · Der Nervenarzt · Cited by 3
ADHS im Erwachsenenalter (ICD-10 F90)
Rösler, M., Heßlinger, B., & Philipsen, A. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50024-1 · Cited by 3
Empfehlungen zur Diagnostik und Therapie der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) im Erwachsenenalter
Baud, P., Eich‐Höchli, D., Kasper, J., Ryffel-Rawak, D., Wälchli, A., Hofecker, M., & Stieglitz, D. (2007) · Schweizer Archiv für Neurologie und Psychiatrie · doi:10.4414/sanp.2007.01859 · Cited by 3
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Mrazek, D. A., & Schak, K. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50055-x · Cited by 3
Microtemporal Dynamics of Dietary Intake, Physical Activity, and Impulsivity in Adult Attention-Deficit/Hyperactivity Disorder: Ecological Momentary Assessment Study Within Nutritional Psychiatry
Ruf, A., Neubauer, A. B., Koch, E. D., Ebner‐Priemer, U., Reif, A., & Matura, S. (2023) · JMIR Mental Health · doi:10.2196/46550 · Cited by 2
“Despite the high efficacy of pharmacotherapy for the short-term treatment of ADHD [8], not every patient responds to medication (eg, 24% of nonresponders [9]), long-term effects of pharmacotherapy are understudied [8], and some studies suggest that pharmacological treatment is positively associated with symptom severi…”
Background
Categorical and dimensional aspects of stimulant medication effects in adult patients with ADHD and healthy controls
Thunberg, P., Reingardt, M., Rode, J., & Msghina, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412178 · Cited by 2
Physical exercise as add-on treatment in adults with ADHD – the START study: a randomized controlled trial
Svedell, L. A., Lindvall, M. A., Lidström-Holmqvist, K., Cao, Y., & Msghina, M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1690216 · Cited by 3
Clinical Trial Designs for Rare Disorders
Steenbergen, A. V., Kaur, M., Rubanarayana, K., & Bolduc, F. V. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200373 · Cited by 2
Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Huang, J., Mauche, N., Rullmann, M., Ulke, C., Becker, G., Patt, M., Zientek, F., Hesse, S., Sabri, O., & Strauß, M. (2022) · Brain Sciences · doi:10.3390/brainsci12080965 · Cited by 3
“About 30% to 42% patients cannot benefit from their medication [19,20].”
Background
Effect of amphetamines on blood pressure
Chan, M., Chan, J. J., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007896.pub4 · Cited by 6
Individual Differences in the Neurocognitive Effect of Movement During Executive Functioning in Children with ADHD: Impact of Subtype, Severity, and Gender
Hoy, B.-A., Feehely, M., Bi, M., Lam, M., Abdalmalak, A., & Fenesi, B. (2025) · Brain Sciences · doi:10.3390/brainsci15060623 · Cited by 2
Attention Deficit Hyperactivity Disorder and Its Treatment in Geriatrics
Deshmukh, P., & Patel, D. D. (2020) · Current Developmental Disorders Reports · doi:10.1007/s40474-020-00194-x · Cited by 3
¿Son los estimulantes efectivos en el tratamiento de los déficits de funciones ejecutivas? Resultados de un estudio aleatorizado doble ciego sobre tratamiento con metilfenidato OROS en adultos con trastorno por déficit de atención con hiperactividad
Biederman, J., Mick, E. O., Fried, R. S., Wilner, N., Spencer, T. J., & Faraone, S. V. (2012) · Psiquiatría Biológica · doi:10.1016/j.psiq.2012.02.004 · Cited by 2
Self-citation
Pharmakotherapie bei Kindern und Jugendlichen mit ADHS
Pelz, R., Banaschewski, T., & Becker, K. (2008) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-008-1729-4 · Cited by 2
An Investigation of the Effects of Neurofeedback Training on Attention Deficit-Hyperactivity Disorder (ADHD) Symptoms, Depression, Anxiety, and Academic Self-Efficacy in College Students.
Harris, S. (2017) · Journal of International Crisis and Risk Communication Research · Cited by 2
Pharmacological treatment for attention deficit hyperactivity disorder in adults
Kweon, K. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.1.49 · Cited by 2
Treatment
Kooij, J. J. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82812-7_4 · Cited by 2

Authors: Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S.
Affiliations: Harvard University (US)
Corresponding author: Spencer, Thomas
ORCID: Spencer, Thomas
Biederman, Joseph
Wilens, Timothy
Surman, Craig
Mick, Eric
Faraone, Stephen
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2005-03
Volume: 57
Issue: 5
Pages: 456-463
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2004.11.043
OpenAlex: W2053924394
Cited by: 385
References: 60
Citations by year: 2026: 6 · 2025: 11 · 2024: 8 · 2023: 16 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 7 · 2017: 15 · 2016: 12 · 2015: 15 · 2014: 16 · 2013: 19 · 2012: 25
FWCI: 21.35
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (R29MH57511, R29MH057511)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: methylphenidate, adult ADHD, ADHD medication, placebo response, dose-response relationship, depressive symptoms, anxiety symptoms, psychiatric comorbidity, treatment safety
MeSH terms: Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Demography, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Methylphenidate, Middle Aged, Neuropsychological Tests, Placebos, Psychiatric Status Rating Scales, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks